A Multi-centre Prospective Non-interventional Clinical Investigation Studying the Glycaemic Control in Patients With Type 1 Diabetes When Introducing a NovoPen® 6 for Treatment With Tresiba® (Insulin Degludec) & Fiasp® (Fast-acting Insulin Aspart) in a Real-world Setting
Latest Information Update: 04 Oct 2024
At a glance
- Drugs Insulin aspart (Primary) ; Insulin degludec (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms CONNECT 1
- Sponsors Novo Nordisk
Most Recent Events
- 30 Sep 2024 Status changed from recruiting to completed.
- 19 Sep 2023 Planned End Date changed from 5 Mar 2024 to 5 Sep 2024.
- 19 Dec 2022 Planned primary completion date changed from 6 Feb 2023 to 5 Mar 2024.